Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 22 Breast Neoplasms 21 Polycystic Ovary Syndrome 12 Carcinoma, Non-Small-Cell Lung 11 Colorectal Neoplasms 10 Lung Neoplasms 8 Endometrial Neoplasms 7 Pancreatic Neoplasms 6 Neoplasms 6 Glioblastoma 5 Rectal Neoplasms 4 Melanoma 4 Lymphoma, Large B-Cell, Diffuse 4 Insulin Resistance 4 Adenocarcinoma of Lung 4 Adenocarcinoma 4 Uterine Cervical Neoplasms 3 Leukoplakia, Oral 3 Urinary Bladder Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Obesity 2 Neoplasm Metastasis 2 Liver Neoplasms 2 Leukemia, Myeloid, Acute 2 Hyperandrogenism 2 Esophageal Neoplasms 2 Erythroplasia 2 Endometrial Hyperplasia 2 Diabetes Mellitus 2 Colonic Neoplasms 2

Interventions

Sunitinib 64 Nivolumab 54 Sorafenib 38 Bevacizumab 35 Axitinib 35 pembrolizumab 34 Everolimus 30 cabozantinib 29 pazopanib 26 aldesleukin 26 Ipilimumab 23 Interleukin-2 19 Specimen Handling 17 Magnetic Resonance Spectroscopy 17 Gemcitabine 17 lenvatinib 16 Interferon-alpha 15 Interferon alpha-2 13 Radiosurgery 12 Cyclophosphamide 12 fludarabine phosphate 11 atezolizumab 10 durvalumab 8 Introns 8 Erlotinib Hydrochloride 8 Biopsy 8 temsirolimus 7 avelumab 7 Radiotherapy 7 Capecitabine 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Renal Cell × Metformin × Clear all

NCT06884683 2025-03-19

NivoMet

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase 2 Terminated

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡